Objective: To assess the reliability, validity, responsiveness, and minimally important difference (MID) of the Incontinence Quality of Life (I-QOL) questionnaire in patients with urinary incontinence due to neurogenic detrusor overactivity.
Design: Randomized, double-blind, multicenter, placebo-controlled study.
Setting: Eight centers across Belgium, France, and Switzerland.
Participants: Patients with urinary incontinence due to neurogenic detrusor overactivity inadequately managed on oral anticholinergics. Fifty-nine patients (spinal cord injury, n=53; multiple sclerosis, n=6) were enrolled.
Intervention: Single dose of botulinum toxin type A (Botox) (200 or 300 U) or placebo.
Main Outcome Measures: I-QOL questionnaire completed at screening and over a 24-week post-treatment period.
Results: The Cronbach alpha ranged from .79 to .93, indicating that I-QOL is a reliable measure of QOL in neurogenic urinary incontinence patients. No item had more than 5.1% missing or out of range values. With the exception of 2 items, questions showed acceptable item-scale correlation and scaling success results varied by domain. Post-treatment correlations indicated acceptable construct validity. The I-QOL was responsive to improvements in symptoms. MID values ranged from 4 to 11 points.
Conclusions: Results suggest that I-QOL is a reliable, valid, and responsive measure of incontinence-related QOL in neurogenic patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.apmr.2007.02.009 | DOI Listing |
Surgery
January 2025
South Auckland Clinical Campus, The University of Auckland, Auckland, New Zealand.
Background: Excisional hemorrhoidectomy and stapled hemorrhoidopexy are 2 common procedures for treating symptomatic hemorrhoids. However, concerns persist regarding the risk of postoperative complications and their unclear prevalence in the literature. This systematic review aims to evaluate and compare the prevalence of incontinence after stapled hemorrhoidopexy and excisional hemorrhoidectomy.
View Article and Find Full Text PDFBJU Int
January 2025
Department of Urology, Mayo Clinic Arizona, Phoenix, AZ, USA.
Objectives: To compare postoperative complication rates of patients with metabolic syndrome (MetS) with patients without MetS after holmium laser enucleation of the prostate (HoLEP) for management of benign prostatic hyperplasia (BPH).
Patients And Methods: We retrospectively reviewed patients aged >40 years who underwent HoLEP at our institution from 2007 to 2022. Criteria for MetS were diagnoses of at least three of the following: diabetes mellitus, hypertension, hyperlipidaemia, or obesity (body mass index ≥30 kg/m).
Vet Rec
January 2025
Department of Clinical Science and Services, Royal Veterinary College, Hatfield, UK.
Background: Pugs and French bulldogs (FBDs) are commonly presented for spinal disease. The aim of this study was to define the most common spinal diseases in both breeds.
Methods: This was a monocentric retrospective study including pugs and FBDs presenting with clinical signs consistent with spinal disease between 2010 and 2022.
Asian J Endosc Surg
January 2025
Department of Urology, Kanagawa Cancer Center, Yokohama, Japan.
Introduction: The Retzius-sparing technique for prostate cancer has shown favorable continence recovery outcomes. Magnetic resonance imaging after Retzius-sparing showed that the bladder anterior wall is widely connected to the abdominal wall, which contributes to urinary continence. We aimed to evaluate whether the Peritoneal Fixation technique, which involves suturing the anterior bladder wall onto the abdominal wall above the pubic bone, contributes to the recovery of urinary continence.
View Article and Find Full Text PDFJ Endourol
January 2025
Urological Research Network, Miami Lakes, Florida, USA.
Focal therapy (FT) is an emerging option for intermediate-risk prostate cancer (IR-PCa). Transperineal MRI fusion laser ablation of PCa (TPFLA) is a novel FT technique with limited data reported. We conducted a phase I clinical trial evaluating the safety, feasibility, and 1-year oncologic results for patients with IR-PCa treated with TPFLA in an office setting.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!